Gilder Gagnon Howe & Co. LLC Sells 14,494 Shares of Boston Scientific Co. (NYSE:BSX)

Gilder Gagnon Howe & Co. LLC cut its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,216,397 shares of the medical equipment provider's stock after selling 14,494 shares during the quarter. Boston Scientific makes up 1.2% of Gilder Gagnon Howe & Co. LLC's investment portfolio, making the stock its 21st largest position. Gilder Gagnon Howe & Co. LLC owned about 0.08% of Boston Scientific worth $108,649,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of BSX. Mechanics Bank Trust Department purchased a new position in Boston Scientific during the fourth quarter worth about $415,000. Highland Capital Management LLC purchased a new stake in shares of Boston Scientific during the 4th quarter valued at $4,887,000. Covenant Asset Management LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth $3,405,000. Brookstone Capital Management raised its position in shares of Boston Scientific by 23.7% in the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock worth $9,455,000 after buying an additional 20,307 shares during the period. Finally, Beacon Investment Advisory Services Inc. grew its position in Boston Scientific by 31.7% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock valued at $1,744,000 after acquiring an additional 4,702 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BSX shares. BTIG Research restated a "buy" rating and issued a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, April 23rd. Needham & Company LLC lifted their target price on shares of Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, April 24th. Evercore ISI increased their price target on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Citigroup boosted their price objective on Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Finally, Truist Financial increased their target price on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Twenty-three equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $114.52.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $0.71 during trading on Thursday, hitting $103.58. 2,529,090 shares of the company traded hands, compared to its average volume of 6,324,273. Boston Scientific Co. has a one year low of $70.97 and a one year high of $107.17. The stock has a market capitalization of $153.21 billion, a price-to-earnings ratio of 82.74, a PEG ratio of 2.79 and a beta of 0.73. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The business's fifty day moving average is $98.53 and its 200-day moving average is $95.13.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 earnings per share. As a group, equities analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other news, CFO Daniel J. Brennan sold 67,333 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the sale, the chief financial officer now owns 225,808 shares in the company, valued at $23,764,033.92. This represents a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Bradley Sorenson sold 1,201 shares of Boston Scientific stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the transaction, the executive vice president now directly owns 25,443 shares in the company, valued at approximately $2,704,845.33. This trade represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 138,009 shares of company stock worth $14,407,381 over the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.